Julia Elvin
Overview
Explore the profile of Julia Elvin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
533
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Huang R, Haberberger J, Severson E, Duncan D, Hemmerich A, Edgerly C, et al.
Mod Pathol
. 2020 Sep;
34(2):252-263.
PMID: 32884129
PD-L1 immunohistochemistry (IHC) currently has the most Food and Drug Administration (FDA) approvals as a companion diagnostic (CDx) for immunotherapies in specific tumor types; however, multiple other immunotherapy biomarkers exist....
12.
Huang R, Li X, Haberberger J, Sokol E, Severson E, Duncan D, et al.
Oncologist
. 2020 Sep;
25(11):943-953.
PMID: 32869930
Background: We examined the current biomarker landscape in breast cancer when programmed death-ligand 1 (PD-L1) testing is integrated with comprehensive genomic profiling (CGP). Material And Methods: We analyzed data from...
13.
Valiakhmetova A, Gorelyshev S, Konovalov A, Trunin Y, Savateev A, Kram D, et al.
Oncologist
. 2020 Feb;
25(2):e198-e202.
PMID: 32043779
For pediatric patients with high-grade gliomas, standard-of-care treatment includes surgery, chemotherapy, and radiation therapy; however, most patients ultimately succumb to their disease. With advances in genomic characterization of pediatric high-grade...
14.
Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition
Campos M, Cohen M, Von Euw E, Velculescu V, Kujak J, Conklin D, et al.
JCO Precis Oncol
. 2019 Dec;
2.
PMID: 31799491
No abstract available.
15.
Fehniger J, Berger A, Juckett L, Elvin J, Levine D, Zajchowski D
Gynecol Oncol
. 2019 Nov;
155(3):473-482.
PMID: 31703812
Objective: We analyzed comprehensive genomic sequencing results from paired ovarian cancer samples to identify changes in mutational events over time. Methods: DNA from paired FFPE tumor samples from 50 ovarian...
16.
Mikubo M, Seto K, Kitamura A, Nakaguro M, Hattori Y, Maeda N, et al.
J Thorac Oncol
. 2019 Oct;
15(1):130-137.
PMID: 31605798
Comprehensive genetic panel testing generally requires that the analyzed tissues have a percent tumor nuclei (%TN) content of 20% or more to achieve assay performance comparable to the validated specifications....
17.
Bianchi A, Lopez S, Altwerger G, Bellone S, Bonazzoli E, Zammataro L, et al.
Gynecol Oncol
. 2019 Aug;
155(1):144-150.
PMID: 31434613
Objectives: Cervical cancer (CC) remains a major health problem worldwide. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors (PARPi) have emerged as a promising class of chemotherapeutics in ovarian cancer. We...
18.
Ramkissoon L, Britt N, Guevara A, Whitt E, Severson E, Sathyan P, et al.
Curr Treat Options Oncol
. 2018 Jun;
19(8):41.
PMID: 29931654
In recent years, large-scale genomic studies have expanded our knowledge regarding genomic drivers in tumors of the central nervous system. While histopathologic analysis of brain tumors remains the primary method...
19.
Severson E, Riedlinger G, Connelly C, Vergilio J, Goldfinger M, Ramkissoon S, et al.
Blood
. 2018 Apr;
131(22):2501-2505.
PMID: 29678827
No abstract available.
20.
Bellone S, Buza N, Choi J, Zammataro L, Gay L, Elvin J, et al.
Clin Cancer Res
. 2018 Jan;
24(14):3282-3291.
PMID: 29351920
Ovarian carcinoma no longer responsive to surgery and chemotherapy remains an incurable disease. Alternative therapeutic options remain desperately needed. We describe a heavily pretreated patient with ovarian cancer with recurrent...